A Proof of Biological Efficacy Study Assessing the Potential of Piboserod a Specific 5-HT4 Antagonist for the Treatment of Symptomatic Congestive Heart Failure in stable outpatients NYHA class II-III on top of Usual Evidence Based Pharmacological treatment

Bio-Medisinsk Innovasjon AS0 个研究点目标入组 156 人开始时间: 2005年12月1日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1. Males and females
•2. Aged 18 –80 years, both inclusive.
•3. Symptomatic, systolic heart failure (NYHA class II-IV), cardiomyopathic or ischemic, for at least 3 months, based on relevant symptoms and locally determined (by cardiac magnetic resonance imaging, echo-cardiography, LV angiography, or radionuclide angiocardiography) systolic left ventricular dysfunction corresponding to LVEF = 0.35
•4. Stable sinus rhythm
•5. Receiving stable, evidence-based pharmacological treatment for CHF for at least 14 days (if on beta-blockers, for at least 2 months) and with no current plan for changing therapy
•6. Ability to conduct regular visits to the clinic
•7. Signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Unstable patients hospitalised within last 2 weeks, baseline prolongation of QTc interval> 450ms, atrial fibrillation at randomisation, MI or re-vascularisation last 3 months, stroke last 3 months, acute myocarditis or constrictive pericarditis, symptomatic bradycardia or 2nd or 3rd degree AV-block (atrioventricular block), planned major surgery including cardiac revascularisation, symptomatic hypotension or uncontrolled hypertension, clinically significant diseases as specified in protocol.

发起方